Show simple item record

dc.contributor.authorvan Vuuren, BJ
dc.contributor.authorBergseth, G
dc.contributor.authorMollnes, TE
dc.contributor.authorShaw, AM
dc.date.accessioned2015-04-23T09:15:27Z
dc.date.issued2014-01-15
dc.description.abstractElectroluminescent assays for epitopes on the complement components C3dg, terminal complement complex (TCC) and factor B/Bb (fB/Bb) have been developed with capture and detection antibodies to produce detection limits C3dg=91±9ng/mL, TCC=3±0.1ng/mL and fB=55.7±0.1ng/mL. The assay performance was assessed against a series of zymosan and heat aggregated IgG (HAIgG) in vitro activations of complement using a calibrated activated complement serum (ACS) as calibration standard. The ACS standard was stable within 20% accuracy over a 6-month period with freeze-thaw cycles as required. Differential activation of the complement cascade was observed for TCC showing a pseudo-first order formation half-life of 3.5h after activation with zymosan. The C3dg activation fragment indicates a 10% total activation for both activation agents. The kinetic-epitope analysis for fB indicates that the capture epitope is on the fB/Bb protein fragment which can then become covered by the formation of C3bBb or C3bBbP complexes during the time course of the cascade.en_GB
dc.description.sponsorshipUniversity of Exeteren_GB
dc.identifier.citationVol. 402, Iss. 1-2, pp. 50 - 56en_GB
dc.identifier.doi10.1016/j.jim.2013.11.010
dc.identifier.otherS0022-1759(13)00326-8
dc.identifier.urihttp://hdl.handle.net/10871/16970
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/24287422en_GB
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S0022175913003268en_GB
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Journal of Immunological Methods. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Immunological Methods, Vol. 402, Iss. 1-2, pp. 50 – 56 doi:10.1016/j.jim.2013.11.010en_GB
dc.subjectActivationen_GB
dc.subjectAssaysen_GB
dc.subjectCascadeen_GB
dc.subjectComplementen_GB
dc.subjectElectroluminescenten_GB
dc.subjectEpitopeen_GB
dc.subjectCalibrationen_GB
dc.subjectComplement Activationen_GB
dc.subjectComplement C3ben_GB
dc.subjectComplement Factor Ben_GB
dc.subjectComplement Membrane Attack Complexen_GB
dc.subjectElectrochemical Techniquesen_GB
dc.subjectEpitopesen_GB
dc.subjectFreezingen_GB
dc.subjectHalf-Lifeen_GB
dc.subjectHumansen_GB
dc.subjectImmunoassayen_GB
dc.subjectImmunoglobulin Gen_GB
dc.subjectKineticsen_GB
dc.subjectLimit of Detectionen_GB
dc.subjectLuminescent Measurementsen_GB
dc.subjectPeptide Fragmentsen_GB
dc.subjectReference Standardsen_GB
dc.subjectZymosanen_GB
dc.titleElectroluminescent TCC, C3dg and fB/Bb epitope assays for profiling complement cascade activation in vitro using an activated complement serum calibration standard.en_GB
dc.typeArticleen_GB
dc.date.available2015-04-23T09:15:27Z
dc.identifier.issn0022-1759
exeter.place-of-publicationNetherlands
dc.descriptionJournal Articleen_GB
dc.descriptionCopyright © 2013 Elsevier B.V. All rights reserved.en_GB
dc.identifier.journalJournal of Immunological Methodsen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record